The initial excitement has since led to at least 90 monotherapy clinical trials on a wide range of human cancers with several generations of either natural or synthetic small molecule inhibitors that all bind to the N-terminal denosine triphosphate/Adenosine diphosphate binding site of Hsp90 proteins (see ClinicalTrials.gov). Here, HSP90AB1 is linked to cancer.